Unrecognized wild-type transthyretin amyloidosis may be present in up to 10% to 15% of older adults with heart failure, highlighting the need for early noninvasive diagnosis and emerging therapies.
Older adults with heart failure, specifically focusing on transthyretin amyloid cardiomyopathy (ATTR-CM)
Transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure in older adults that can now be diagnosed noninvasively and treated with disease-modifying pharmaceutical therapies.
甲状腺素转运蛋白淀粉样变性心肌病（ATTR-CM）是老年人心力衰竭（HF）中一种未被充分认识的病因，源于错误折叠的甲状腺素转运蛋白（TTR）或前白蛋白在心肌中的沉积。超声心动图和心脏磁共振的特征性表现可强烈提示该病，但不能诊断确诊。在无单克隆蛋白证据时，可通过无创核医学影像技术进行诊断。淀粉样纤维的形成，源于遗传性ATTR淀粉样变性（hATTR）中的致不稳定突变，或野生型ATTR淀粉样变性（wtATTR）中与年龄相关的过程。最新研究表明多达10%至15%的老年心衰患者可能存在未被识别的wtATTR。相关表现如腕管综合征和腰椎管狭窄可提高怀疑度，并可能为早期诊断提供途径。此前仅能通过器官移植治疗，现在已有药物治疗可减缓或阻止ATTR-CM进展并改善临床结局。早期识别仍然是实现最佳治疗效果的关键。
Building similarity graph...
Analyzing shared references across papers
Frederick L. Ruberg
Martha Grogan
Mazen Hanna
Journal of the American College of Cardiology
Boston University
Mayo Clinic
Scripps Research Institute
Building similarity graph...
Analyzing shared references across papers
Ruberg等人在《Transthyretin amyloid cardiomyopathy (ATTR-CM)》中综述指出，未被识别的野生型甲状腺素转运蛋白淀粉样变可能存在于多达10%至15%的老年心力衰竭患者中，强调了早期无创诊断和新兴疗法的必要性。
www.synapsesocial.com/papers/69ed841f27c2c78c57d1e0cc — DOI: https://doi.org/10.1016/j.jacc.2019.04.003
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: